Clinical Report: Sex-Specific Lipid Biomarkers for Cardiovascular Risk Prediction in Women

Overview

This editorial highlights sex-specific differences in lipid biomarkers predicting major adverse cardiovascular events (MACE) in high-risk patients. It emphasizes that traditional LDL-C may lack prognostic value in treated elderly cohorts, while other markers like remnant cholesterol, ApoA-1, and TG/HDL-C ratio show sex-specific predictive utility.

Background

Atherosclerotic cardiovascular disease is the leading cause of death among women globally, yet risk prediction tools and biomarkers have been predominantly validated in men. Women experience unique lipid-related risk factors influenced by sex hormones and genetics, especially after menopause. Recent guidelines recognize female-specific conditions as risk enhancers, underscoring the need for sex-tailored lipid biomarkers. The study by Schnetzer et al. analyzed lipid biomarkers in a matched cohort of high-risk men and women over 14 years to identify sex-specific predictive differences.

Data Highlights

Key Findings

• LDL-C, the primary lipid management target, showed no prognostic value for MACE in this elderly, statin-treated high-risk cohort.
• Remnant cholesterol predicted cardiovascular events in both men and women, indicating its importance as a residual risk marker.
• ApoA-1 and TG/HDL-C ratio were significant predictors only in women, suggesting sex-specific lipid metabolism influences risk.
• Ceramide-based risk scores (CERT1 and CERT2) predicted events only in men, possibly due to male-dominant derivation cohorts and sex differences in ceramide biology.
• Key biomarkers such as Lp(a) and non-HDL-C were not assessed, limiting comprehensive interpretation of sex-specific lipid risk.
• Therapies like statins, hormone replacement, and omega-3 fatty acids modulate ceramide and phosphatidylcholine metabolism, potentially confounding biomarker performance.

Clinical Implications

Clinicians should consider complementing LDL-C with other lipid parameters such as ApoB or non-HDL-C for cardiovascular risk assessment in women, especially postmenopausal patients. Recognizing sex-specific biomarker profiles may improve risk stratification and guide personalized lipid management. Awareness of therapy effects on lipidomic markers is essential when interpreting biomarker data.

Conclusion

Sex-specific disparities exist in lipid biomarker predictive value for cardiovascular events, underscoring the need for female-tailored risk assessment tools. Incorporating a broader panel of lipid markers beyond LDL-C may enhance risk prediction and management in women.

References

1. Schnetzer et al. 2023 -- Sex-specific disparities in lipid-based prediction of major cardiovascular events